menu search

Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024 WALTHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the […] The post Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corp... Read More
Posted: Mar 31 2023, 00:00
Author Name: forextv
Views: 111344

Search within

Pages Search Results: